| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sands Capital Life Sciences Pulse Fund II, L.P. | 15% | $18,396,000 | 10,950,000 | Sands Capital Life Sciences Pulse Fund II, L.P. | 30 Jun 2025 | |||
| ADAR1 Capital Management, LLC | 9.9% | -0.9% | $12,999,326 | +$1,248,993 | 7,737,694 | +11% | ADAR1 Capital Management GP, LLC | 30 Jun 2025 |
| Fairmount Funds Management LLC | 9.9% | $15,300,494 | 7,018,575 | Fairmount Funds Management LLC | 31 Dec 2024 | |||
| Trails Edge Capital Partners, LP | 5.1% | $9,525,057 | 6,145,198 | Trails Edge Capital Partners, LP | 23 Dec 2025 | |||
| Nantahala Capital Management, LLC | 7.5% | $11,551,000 | 5,298,624 | Nantahala Capital Management, LLC | 31 Dec 2024 | |||
| ARMISTICE CAPITAL, LLC | 5% | $7,693,233 | 3,529,006 | Armistice Capital, LLC | 31 Dec 2024 |
As of 30 Sep 2025, 53 institutional investors reported holding 54,964,771 shares of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT). This represents 46% of the company’s total 120,494,078 outstanding shares.
The largest institutional shareholders of Inhibikase Therapeutics, Inc. - Common Stock, $0.001 par value (IKT) together control 45% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Sands Capital Alternatives, LLC | 9.1% | 10,950,000 | 0% | 3.9% | $17,739,000 |
| Soleus Capital Management, L.P. | 5.2% | 6,325,000 | 0% | 0.55% | $10,246,500 |
| Fairmount Funds Management LLC | 5.1% | 6,125,000 | 0% | 0.89% | $9,922,500 |
| PERCEPTIVE ADVISORS LLC | 4.5% | 5,421,568 | -0.2% | 0.26% | $8,782,940 |
| Commodore Capital LP | 4.5% | 5,397,488 | 0% | 0.43% | $8,743,931 |
| ADAR1 Capital Management, LLC | 4.4% | 5,247,603 | +2.5% | 0.85% | $8,501,117 |
| VANGUARD GROUP INC | 2.7% | 3,273,339 | +1.5% | 0% | $5,302,809 |
| BlackRock, Inc. | 2.6% | 3,075,186 | +13% | 0% | $4,981,802 |
| Blackstone Inc. | 2.2% | 2,638,276 | 0% | 0.02% | $4,274,007 |
| Nantahala Capital Management, LLC | 1.8% | 2,190,000 | 0% | 0.22% | $3,547,800 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.92% | 1,112,574 | +4.3% | 0% | $1,802,466 |
| Stonepine Capital Management, LLC | 0.61% | 735,019 | +0.17% | 0.97% | $1,190,731 |
| STATE STREET CORP | 0.42% | 507,749 | +28% | 0% | $822,553 |
| NORTHERN TRUST CORP | 0.31% | 374,336 | -4.7% | 0% | $606,424 |
| BLAIR WILLIAM & CO/IL | 0.13% | 152,953 | -2.5% | 0% | $247,784 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.13% | 152,298 | 0% | 0% | $246,723 |
| Bank of New York Mellon Corp | 0.12% | 138,667 | +4.7% | 0% | $224,641 |
| UBS Group AG | 0.11% | 136,280 | +252% | 0% | $220,773 |
| FMR LLC | 0.09% | 105,770 | -27% | 0% | $171,347 |
| BARCLAYS PLC | 0.07% | 85,578 | -22% | 0% | $138,636 |
| DEUTSCHE BANK AG\ | 0.07% | 80,496 | 0% | $130,404 | |
| Nuveen, LLC | 0.07% | 78,659 | 0% | 0% | $127,428 |
| CITADEL ADVISORS LLC | 0.06% | 71,670 | 0% | $116,105 | |
| RHUMBLINE ADVISERS | 0.05% | 57,551 | -1.7% | 0% | $93,226 |
| MORGAN STANLEY | 0.05% | 56,019 | -44% | 0% | $90,753 |
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q3 | 54,964,771 | $89,043,214 | +$712,913 | $1.62 | 53 |
| 2025 Q2 | 54,512,097 | $106,299,597 | +$5,482,915 | $1.95 | 48 |
| 2025 Q1 | 51,462,756 | $112,702,942 | +$3,027,391 | $2.19 | 47 |
| 2024 Q4 | 50,059,308 | $162,691,896 | +$161,164,566 | $3.25 | 31 |
| 2024 Q3 | 860,232 | $1,118,330 | +$30,199 | $1.30 | 11 |
| 2024 Q2 | 836,496 | $1,021,038 | +$723,392 | $1.21 | 12 |
| 2024 Q1 | 205,558 | $443,782 | -$62,189 | $2.16 | 12 |
| 2023 Q4 | 235,004 | $298,925 | -$271,105 | $1.27 | 11 |
| 2023 Q3 | 429,662 | $597,627 | -$496,804 | $1.39 | 13 |
| 2023 Q2 | 747,138 | $2,693,647 | +$2,394,677 | $3.61 | 14 |
| 2023 Q1 | 82,817 | $54,460 | +$54,460 | $0.66 | 1 |